TNF-α Inhibitors and HBV Reactivation Risk in HBsAg-/Anti-HBc+ Patients: A Systematic Review and Meta-Analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Liver international : official journal of the International Association for the Study of the Liver
- Publicado em
- 1 mar 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
TNF-α Inhibitors and HBV Reactivation Risk in HBsAg-/Anti-HBc+ Patients: A Systematic Review and Meta-Analysis
Meng Hsuan Kuo, Ping-Hung Ko, Chen-Chou Lee, Chih-Wei Tseng
Descritores MeSH
- Tumor Necrosis Factor Inhibitors
- Hepatitis B
- Hepatitis B virus
- Tumor Necrosis Factor-alpha
- Virus Activation
- Humans
- Hepatitis B Antibodies
- Hepatitis B Core Antigens
- Hepatitis B Surface Antigens
Veja também
Estudos relacionados
- What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis
- Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy
- Global prevalence of occult hepatitis B virus infection in HBcAb-positive individuals: a systematic review and meta-analysis
- Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment